Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30787952 | 0.96 | ACE (0.44) | ACEVCAM1PPARGPPARAKIF11 | |
| SCHEMBL30093819 | 0.90 | HDAC6 (0.41) | FAAHHDAC6HDAC1KIF11 | |
| SCHEMBL29455274 | 0.86 | ITGB3 (0.41) | FAAHHDAC6HDAC1KIF11 | |
| SCHEMBL13753519 | 0.83 | GPR88 (0.37) | ACEFAAHHDAC6KIF11 | |
| SCHEMBL22415062 | 0.81 | PTPN1 (0.42) | ACEKIF11 | |
| SCHEMBL18735705 | 0.80 | HDAC3 (0.39) | FAAHHDAC6HDAC1KIF11 | |
| SCHEMBL17193610 | 0.78 | KIF11 (0.37) | KIF11 | |
| SCHEMBL4835726 | 0.78 | KIF11 (0.42) | KIF11 | |
| SCHEMBL23001074 | 0.77 | NOD1 (0.57) | FAAH | |
| SCHEMBL17817607 | 0.77 | NOD1 (0.57) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127797-A1 | PRODRUG COMPRISING A DRUG-LINKER CONJUGATE | ASCENDIS PHARMA A/S (DK) | 2025-04-24 | — | — | US | disclosed |
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA GMBH (DE) | 2024-02-08 | — | — | US | disclosed |
| US-20220331334-A1 | Prodrug Comprising a Drug-Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2022-10-20 | — | — | US | disclosed |
| EP-3981761-A2 | INTERMEDIATES FOR PRODRUGS | Ascendis Pharma A/S (DK) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | ACE 1053/4885FAAH 1647/4885VCAM1 3280/4885 |
| US-20220331334-A1 | Prodrug Comprising a Drug-Linker Conjugate | H1-0, H1-3, DLST | ACE 915/4885FAAH 1624/4885VCAM1 3100/4885 |
| US-20250127797-A1 | PRODRUG COMPRISING A DRUG-LINKER CONJUGATE | H1-0, H1-3, DLST | ACE 915/4885FAAH 1624/4885VCAM1 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.